Evidence map›Paper›PMID 37742030›Full record

ArticleClinical epigenetics2023

METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.

Kesong Shi, Rula Sa, Le Dou, Yuan Wu, Zhiqiang Dong, Xinyao Fu, Haiquan Yu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. The Emerging Role of METTL3 in Lung Diseases.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kesong Shi *State Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China.
Rula Sa *State Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China.
Le Dou *State Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China.
Yuan WuState Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China.
Zhiqiang DongState Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China.
Xinyao FuState Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China.
Haiquan YuState Key Laboratory of Reproductive Regulation a Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, 010070, Inner Mongolia, China. hyu@imu.edu.cn.
Inner Mongolia University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple genetic and epigenetic regulatory mechanisms play a vital role in tumorigenesis and development. Understanding the interplay between different epigenetic modifications and its contribution to transcriptional regulation in cancer is essential for precision medicine. Here, we aimed to investigate the interplay between N6-methyladenosine (m6A) modifications and histone modifications in lung adenocarcinoma (LUAD).

resultsBased on the data from public databases, including chromatin property data (ATAC-seq, DNase-seq), methylated RNA immunoprecipitation sequencing (MeRIP-seq), and gene expression data (RNA-seq), a m6A-related differentially expressed gene nerve growth factor inducible (VGF) was identified between LUAD tissues and normal lung tissues. VGF was significantly highly expressed in LUAD tissues and cells, and was associated with a worse prognosis for LUAD, silencing of VGF inhibited the malignant phenotype of LUAD cells by inactivating the PI3K/AKT/mTOR pathway. Through the weighted correlation network analysis (WGCNA) and integration of TCGA-LUAD RNA-seq and m6A methyltransferase METTL3-knockdown RNA-seq data, a significant positive correlation between METTL3 and VGF was observed. By using the MeRIP-qPCR and dual-luciferase reporter assays, we demonstrated that METTL3 knockdown decreased m6A modification level of VGF coding sequences in LUAD cells, the colorimetric m6A quantification assay also showed that METTL3 knockdown significantly decreased global m6A modification level in LUAD cells. Interestingly, we found that METTL3 knockdown also reduced VGF expression by increasing H3K36me3 modification at the VGF promoter. Further research revealed that METTL3 knockdown upregulated the expression of histone methylase SETD2, the major H3K36me3 methyltransferase, by methylating the m6A site in the 3'UTR of SETD2 mRNA in LUAD cells.

conclusionsOverall, our results reveal that the expression of VGF in LUAD cells is regulated spatio-temporally by METTL3 through both transcriptional (via histone modifications) and post-transcriptional (via m6A modifications) mechanisms. The synergistic effect of these multiple epigenetic mechanisms provides new opportunities for the diagnosis and precision treatment of tumors.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMethyltransferasesDNA MethylationHistone CodeHumansNerve Growth FactorsPhosphatidylinositol 3-KinasesMethyltransferasesMETTL3 protein, humanNerve Growth FactorsPhosphatidylinositol 3-KinasesVGF protein, humanHistone modificationLung adenocarcinomam6A modificationMETTL3VGF

Identifiers

PMID37742030
PMCPMC10517543
OpenAlexW4386980885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.